Eyenovia patent expiration
1. Clobetasol Propionate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11376262 | EYENOVIA | Method of treating an inflammatory or infectious disease |
May, 2036
(11 years from now) | |
| US10588913 | EYENOVIA | Aqueous suspension agent containing glucocorticosteroid nanoparticles |
May, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2027 |
Drugs and Companies using CLOBETASOL PROPIONATE ingredient
Market Authorisation Date: 04 March, 2024
Treatment: Treatment of inflammation
Dosage: SUSPENSION/DROPS
More Information on Dosage
CLOBETASOL PROPIONATE family patents
2. Mydcombi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11398306 | EYENOVIA | Ophthalmic drug delivery |
Jul, 2031
(6 years from now) | |
| US10839960 | EYENOVIA | Ophthalmic drug delivery |
Jul, 2031
(6 years from now) | |
| US11839487 | EYENOVIA | Ophthalmic drug delivery |
Jul, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 05, 2026 |
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE ingredient
Market Authorisation Date: 05 May, 2023
Treatment: Method of administering an effective dose of tropicamide and phenylephrine hydrochloride to an eye
Dosage: SPRAY, METERED
More Information on Dosage
MYDCOMBI family patents